Back to News
Market Impact: 0.2
SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
SOPHiA GENETICS and Myriad Genetics announced a collaboration to advance prostate cancer-specific genomic instability score (PrGIS) technology in support of precision oncology approaches with AstraZeneca. The announcement provides no financial terms, timeline, or clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
AZN0.30
MYGN0.45
SOPH0.45
More News
- For the final 10% of cystic fibrosis, the breakthrough still hasn't come
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- Israel’s economy prospers despite years of war, but prices worry voters
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- SpaceX to buy key spectrum that could help Starlink Mobile become major US cell carrier
- Why is T-Mobile stock tumbling today?